Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures, which might be useful in the treatment of cancers, and vascular and metabolic diseases; and LB-200 series for the treatment of chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; pharmacologic study with the National Cancer Institute; and clinical research support agreement with City of Hope National Medical Center to carry out a Phase 1b clinical trial of its LB-100, a protein phosphatase inhibitor for small cell lung cancer. The company was incorporated in 2005 and is based in East Setauket, New York.
IPO Year:
Exchange: NASDAQ
Website: lixte.com
| Date | Price Target | Rating | Analyst |
|---|
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4/A - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)
4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)
4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)
4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)
4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)
4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)
4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)
4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)
3 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)
4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)
3 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)
4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)
PRE 14A - NOMAD POWER SOLUTIONS, INC. (0001335105) (Filer)
8-K - NOMAD POWER SOLUTIONS, INC. (0001335105) (Filer)
8-K - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Filer)
8-K - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Filer)
8-K - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Filer)
SCHEDULE 13G - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Subject)
8-K - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Filer)
424B5 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Filer)
8-K - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Filer)
10-Q - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Filer)
Live Leadership Updates
Bringing More Than Three Decades of Energy Investment Experience, Mr. Porter Has Helped Build a Global Power Infrastructure Portfolio, Strengthening LIXTE's Strategic Expansion into AI Energy Infrastructure BOCA RATON, Fla., June 01, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), today announced its strategic transformation into an AI energy infrastructure equipment & services platform focused on meeting the rapidly growing power demands of AI and hyperscale data centers. In connection with this transformation, Stuart D. Porter, Founder, Managing Partner, Chief Executive Officer and Chief Investment Officer of Denham Capital Managemen
BOCA RATON, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical stage pharmaceutical and med-tech company focused on advancing cancer treatments, today announced it has appointed Sidney Braun as Chief Executive Officer of the Company's Liora Technologies Europe Ltd. subsidiary ("Liora"). A veteran of the healthcare industry, Braun brings to Liora more than two decades of operational and strategic advisory experience at companies in North America, Europe and Israel. He was instrumental in the creation of Liora and facilitated LIXTE's acquisition of Liora's assets in November 2025 from Orbit Capital, Inc. Over his
-- Company Relocates Corporate Headquarters to Boca Raton -- Boca Raton, Fla., Sept. 03, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today announced that Lourdes Felix and Guy Primus have joined the Company's Board of Directors, and Peter Stazzone has been named Chief Financial Officer. The Company also announced that it has relocated its corporate headquarters to Boca Raton. The new board members succeed Bas van der Baan, who remains Chief Scientific Officer of LIXTE, and René Bernards, PhD, who has been n
PASADENA, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today announced the appointment of Jan Schellens, M.D., Ph.D., as Chief Medical Officer (CMO). Dr. Schellens brings to LIXTE more than 25 years of clinical experience as a medical oncologist, pharmacologist and clinical pharmacologist, including more than two decades developing and bringing new drugs to market. He assumes the CMO role at LIXTE effective August 1, 2024, succeeding James S. Miser, M.D., who is leaving the Company after serv
Biotechnology Veteran Bas van der Baan Brings Precision Oncology Expertise; Founder John S. Kovach Named Executive Chairman PASADENA, CA, Sept. 26, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical stage biotechnology company developing a novel class of cancer therapy called PP2A inhibitors, announced that Bas van der Baan has been named as President and Chief Executive Officer of the Company, and as Vice Chairman of the Board of Directors, effective as of September 26, 2023. He has been a member of LIXTE'S Board of Directors since June 2022. Mr. van der Baan succeeds John S. Kovach, M.D., 87, who founded the Company in 2005 a
PASADENA, CA, June 21, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (NASDAQ:LIXT), a clinical-stage pharmaceutical company focused on developing and commercializing cancer therapies, announced the appointment of Bas van der Baan to its Board of Directors. He will serve as an independent director. Dr. John S. Kovach, Founder and Chief Executive Officer of Lixte, commented, "We are very pleased to welcome Mr. van der Baan to our Board of Directors. Mr. van der Baan has over 20 years of experience in the biotechnology industry with a key focus on oncology and diagnostics. He has extensive knowhow in the journey from clinical development to reimbursement and commercialization
Bernards is internationally recognized for his contributions to the development of effective anti-cancer drugs from their earliest stages through clinical use PASADENA, CA, June 15, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (NASDAQ:LIXT), a clinical-stage pharmaceutical company focused on developing and commercializing cancer therapies, announced the appointment of Professor René Bernards to its Board of Directors. Professor Bernards will serve as an independent director. Dr. John S. Kovach, Founder and Chief Executive Officer of Lixte, commented, "We are very pleased to welcome Professor Bernards to our Board of Directors and we look forward to his insight and
EAST SETAUKET, New York, April 13, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. ("Lixte" or the "Company") (NASDAQ:LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, announced the appointment of Gil N Schwartzberg to its Board of Directors. Mr. Schwartzberg is filling a vacancy created by the resignation of Winson (Sze Chun) Ho, M.D. Dr. John S. Kovach, the Founder and Chief Executive Officer of Lixte, commented, "Gil Schwartzberg has played an important role advising and supporting Lixte since its inception. We are pleased to be welcoming Mr. Schwartzberg to our Board of Directors." Dr. Kovach continue
Fastest customizable press release news feed in the world
Issued on behalf of NOMAD Power Solutions, Inc. (NASDAQ:NMAD), formerly LIXTE Biotechnology Holdings, Inc. (NASDAQ:LIXT)NOMAD Power Solutions, Inc. has completed its corporate name change from LIXTE Biotechnology Holdings, Inc. and begins trading today under the new Nasdaq ticker NMAD, marking its transition into the AI energy infrastructure equipment and services sector following its acquisition of NOMAD Transportable Power SystemsAmerican News Group News CommentaryBOCA RATON, Fla., July 6, 2026 /CNW/ -- The artificial intelligence buildout has run headlong into a physical bottleneck: electricity. Data centers are demanding power faster than the grid can add it through traditional fixed inf
-- New Corporate Identity Reflects Strategic Transition into AI Energy Infrastructure Equipment & Services Sector Following Acquisition of NOMAD Transportable Power Systems -- BOCA RATON, Fla., July 06, 2026 (GLOBE NEWSWIRE) -- NOMAD Power Solutions, Inc. ("NOMAD" or the "Company"), today announced that it has completed its name change from LIXTE Biotechnology Holdings, Inc. (NASDAQ:LIXT) to NOMAD Power Solutions, Inc (NASDAQ:NMAD). The Company’s common stock will begin trading today under its new ticker, NMAD on the Nasdaq Stock Market. Shares under the symbol LIXT ceased trading at the close of market on Thursday, July 2, 2026. The new corporate name reflects the next chapter for the
-Transaction Transforms LIXTE to New Growth Sector Addressing Multi-Billion-Dollar Market of Mobile, Utility-Grade Battery Energy Storage Systems- -Company Plans Corporate Name Change to NOMAD Power Solutions BOCA RATON, Fla./WATERBURY, Vt., July 02, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (NASDAQ:LIXT) ("LIXTE" or the "Company") today announced it has completed the previously announced merger with NOMAD Transportable Power Systems, Inc. ("NOMAD"), a market leader in deployable, utility-grade battery energy storage systems (BESS), In connection with the merger, the Company is issuing to the
BOCA RATON, Fla., June 26, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), today announced its inclusion in the Russell Microcap® Index, effective after the close of the U.S. equity markets on June 26, 2026, as part of the annual Russell U.S. Indexes reconstitution. The reconstituted indexes will take effect at the opening of trading on Monday, June 29, 2026. "LIXTE’s inclusion in the Russell Microcap Index represents an important milestone for the Company and reflects the significant progress we have made over the past year," said Geordan Pursglove, Chief Executive Officer of LIXTE. "Under our new leadership team and strategic directi
Issued on behalf of LIXTE Biotechnology Holdings, Inc. Having entered into definitive documents to combine with NOMAD, LIXTE is set to become NOMAD Power Solutions — a pure-play deployable-power company aimed squarely at the bottleneck throttling the AI boom. And it just put $6.5 million to work before the deal even closes. BOCA RATON, Fla., June 18, 2026 (GLOBE NEWSWIRE) -- World Street Intelligence News Commentary — The most important constraint on the artificial-intelligence boom is no longer the supply of advanced chips. It is something far more old-fashioned: electricity, and the ability to get it to the right place at the right time. Data centers training and running the larges
Issued on behalf of LIXTE Biotechnology Holdings, Inc. Having entered into definitive documents to combine with NOMAD, LIXTE is set to become NOMAD Power Solutions — a pure-play deployable-power company — and is funding NOMAD with $6.5 million before the deal even closes. BOCA RATON, Fla., June 18, 2026 (GLOBE NEWSWIRE) -- USA News Group News Commentary — Wall Street spent the last two years obsessed with who makes the chips that power artificial intelligence. The smarter money is now asking a more basic question: where will all the electricity come from? AI data centers consume staggering, continuous quantities of power, and the grid that is supposed to feed them cannot expand fast
Company to Loan $6.5 Million Prior to Closing to Fund Order Backlog and Working Capital Needs – Combined Company to be Renamed NOMAD Power Solutions, Inc. and Trade Under a New Ticker Symbol BOCA RATON, Fla. & WATERBURY, Vt., June 18, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (NASDAQ:LIXT) ("LIXTE" or the "Company") today provided an update on its previously announced definitive agreement to acquire 100% of NOMAD Transportable Power Systems, Inc. ("NOMAD"), the market leader in deployable, utility-grade battery energy storage systems (BESS). The Company expects the acquisition to close on or about July 1, 2026, subject to the satisfaction of customary closing conditions
Issued on behalf of LIXTE Biotechnology Holdings, Inc. America can build data centers in months, but the electricity to run them can take half a decade to arrive. That gap is becoming one of the biggest investment stories of the decade — and a NASDAQ-listed company is repositioning itself to sit right inside it. BOCA RATON, Fla., June 12, 2026 (GLOBE NEWSWIRE) -- Equity Insider News Commentary — For two years, the story of the artificial-intelligence boom has been told in chips: who designs them, who fabricates them, who can buy enough of them. But a quieter, harder constraint has been forming underneath all of it, and it has nothing to do with silicon. The bottleneck that increasingly d
Issued on behalf of LIXTE Biotechnology Holdings, Inc.One of the most dramatic corporate reinventions of 2026 is taking a clinical-stage biotech and rebuilding it as a power-infrastructure company — aimed squarely at the electricity shortage throttling the AI boom.BOCA RATON, Fla., June 12, 2026 /CNW/ -- USA News Group News Commentary — Corporate reinventions are common; total transformations are rare. Companies pivot products, enter adjacent markets, rebrand. What they rarely do is change what business they are in entirely. Yet that is precisely the bet LIXTE Biotechnology Holdings, Inc. (NASDAQ:LIXT) is making — walking away from its origins as a clinical-stage cancer-drug developer to bec
Company to be Renamed NOMAD Power Solutions • First-to-Market with the Mobile, Utility-Grade 1 MW BESS • Addressing a Multi-Hundred-Billion-Dollar Power Capacity Opportunity BOCA RATON, Fla. & WATERBURY, Vt., June 12, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (NASDAQ:LIXT) ("LIXTE" or the "Company") today announced that it has entered into a definitive agreement to acquire 100% of NOMAD Transportable Power Systems, Inc. ("NOMAD"), the market leader in deployable, utility-grade battery energy storage systems (BESS) and the first company to bring a mobile, utility-grade 1 MW BESS to market. Upon closing, the Company will be renamed NOMAD Power Solutions. "This transaction
Live finance-specific insights
BOCA RATON, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical stage pharmaceutical and med-tech company focused on advancing cancer treatments, today announced it has filed its Annual Report on Form 10-K for the year ended December 31, 2025, with the U.S. Securities and Exchange Commission. The report is available on the Company's website, www.lixte.com, and on the SEC's website, www.sec.gov. "2025 was a transformative and highly productive year for our Company," said Geordan Pursglove, who was named LIXTE's Chairman and Chief Executive Officer in June 2025. "We strengthened LIXTE's foundation by assembling an
Located at the Daresbury site of the renowned UK-based Science and Technology Facilities Council (STFC), with $300+ million invested to date in developing the technology BOCA RATON, Fla., Nov. 25, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT) a biotech company focused on advancing cancer treatments, today announced it has completed the acquisition of Liora Technologies Europe Ltd., a UK-based company pioneering electronically controlled proton therapy systems for treating tumors in various types of cancers. Liora will become a wholly owned subsidiary of LIXTE. The acquisition includes Liora's proprietary flagship technology LiGHT Sys
This live feed shows all institutional transactions in real time.
SC 13G - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Subject)
SC 13G/A - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Subject)
SC 13G - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Subject)